CORONA Remedies working capital

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026
174.85×174.85×
37.86×37.86×
205.72×205.72×
6.99×6.99×
11.08×−109.11×
1.16×1.16×
1.24×1.24×
0.78×0.78×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

CORONA₹2,217.40

CORONA Remedies Ltd.

· Pharma & Health
₹ CrorePeersERISMANKINDAPLLTDALIVUSAKUMSAGARWALEYEHCGADVENZYMESMcap ₹13,562 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY26
31/03/2026
Last 12M
30/09/2026
Inventory Days (DIO)174.85174.85
Receivable Days (DSO)37.8637.86
Payable Days (DPO)205.72205.72
Cash Conversion Cycle (days)6.996.99
Working Capital Turnover-109.1111.08
Asset Turnover1.161.16
Cash Conversion (CFO/Net Income)1.241.24
CFO/EBITDA0.780.78
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.